Personalized cancer combo aims to control advanced lung tumors
NCT ID NCT03523702
Summary
This Phase 2 trial tested a personalized treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC). For patients whose tumors had high levels of a specific marker (PD-L1), researchers combined a 4-week personalized radiation course with an immunotherapy drug (pembrolizumab). The goal was to see if this combination could better control the cancer and prevent its spread compared to the standard treatment of chemotherapy plus radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
Conditions
Explore the condition pages connected to this study.